サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1513667

末梢用薬剤溶出バルーンの世界市場：産業分析、規模、シェア、成長、動向、予測（2024年～2033年）

Peripheral Drug Eluting Balloon Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 273 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
末梢用薬剤溶出バルーンの世界市場：産業分析、規模、シェア、成長、動向、予測（2024年～2033年）
出版日: 2024年07月09日
発行: Persistence Market Research
ページ情報: 英文 273 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界の末梢用薬剤溶出バルーン市場に関する包括的な調査レポートを発表しました。当レポートでは、市場促進要因・動向・市場促進要因・課題を含む重要な市場力学を徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主な洞察

  • 末梢用薬剤溶出バルーンの市場規模（2024年）：9億4,860万米ドル
  • 市場予測値（2033年）：19億5,050万米ドル
  • 世界市場成長率（CAGR 2024～2033年）：8.3%

末梢用薬剤溶出バルーン市場- 調査範囲

末梢用薬剤溶出バルーンは、薬剤を動脈壁に直接送達して再狭窄を抑制し、血流を改善することで、末梢動脈疾患（PAD）の治療に重要な役割を果たしています。これらのバルーンは、病院、診療所、外来センターなど、さまざまなヘルスケア環境で使用されており、患者のさまざまなニーズに対応できるよう、さまざまな薬剤製剤とバルーンサイズを提供しています。PADの有病率の増加、バルーン技術の進歩、低侵襲治療への嗜好の高まりが市場成長の原動力となっています。

市場促進要因：

世界の末梢用薬剤溶出バルーン市場は、世界中で数百万人が罹患しているPADの罹患率の上昇など、いくつかの重要な要因に後押しされています。持続的な薬物送達と再狭窄率の低減を実現する効果的な治療オプションに対する需要が、薬剤溶出バルーンの採用を後押ししています。薬剤のコーティングやデリバリー機構を改良した次世代バルーンの開発など、技術の進歩は治療効果と患者の転帰を向上させます。さらに、低侵襲手術の採用増加や有利な償還政策が、市場の成長にさらに貢献しています。

市場抑制要因：

有望な成長が見込まれるもの、末梢用薬剤溶出バルーン市場は、規制遵守、高コスト、新興市場における認知度の低さといった課題に直面しています。薬剤溶出バルーンの承認と使用に関する厳しい規制は、メーカーに大きなコンプライアンス負担を課しています。また、特にヘルスケア予算が限られている地域では、薬剤溶出バルーンや関連手技のコストが高いことも普及の障壁となっています。さらに、新興諸国ではPADや利用可能な治療オプションに対する認識が低いことも、市場浸透の妨げとなっています。

市場機会

末梢用薬剤溶出バルーン市場は、技術革新、人口動向、ヘルスケアインフラの拡大が大きな成長機会となっています。先進的な薬剤製剤や新しいドラッグデリバリー技術をバルーン機器に組み込むことで、治療成績が向上し、適用範囲が広がると期待されます。特に新興国では、ヘルスケアインフラへの投資が増加しており、新たな市場機会の創出が期待されています。こうした機会を活用し、市場での主導権を維持するには、戦略的提携、研究開発への投資、費用対効果の高いソリューションの導入が不可欠です。

本レポートで扱う主な質問

  • 末梢用薬剤溶出バルーン市場の世界の成長を促進する主な要因は何か？
  • さまざまなヘルスケアシーンで末梢用薬剤溶出バルーンの採用を促進している薬剤処方と用途は何か？
  • 技術の進歩は末梢用薬剤溶出バルーン市場の競合情勢をどのように変えているのか？
  • 末梢用薬剤溶出バルーン市場に貢献している主要企業はどこで、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の末梢用薬剤溶出バルーン市場の新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 薬剤コーティングの革新/開発動向

第4章 付加価値の洞察

  • 地域別の製品採用/使用状況分析
  • 規制シナリオ
  • 技術評価
  • バリューチェーン分析
  • 最近の製品の承認と発売
  • ポーターの分析
  • 製品のUSP分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 薬剤コーティング別
    • 症状別
    • 動脈タイプ別
    • エンドユーザー別
    • 地域別
  • 2024年の市場シナリオ

第7章 世界市場の需要数量分析

  • 過去の市場数量分析（2019年～2023年）
  • 現在・将来の市場数量予測（2024年～2033年）
    • 前年比成長動向分析

第8章 世界市場- 価格分析

  • 薬剤コーティング別の地域価格分析
  • 価格の内訳
    • メーカーレベルの価格設定
    • ディストリビューターレベルの価格設定
  • 世界平均価格分析ベンチマーク
  • 価格設定の前提

第9章 世界市場の需要（金額）分析

  • 過去の市場金額分析（2019年～2023年）
  • 現在・将来の市場金額予測（2024年～2033年）
    • 前年比成長動向分析
    • 絶対的利益の機会分析
  • 収益機会シナリオ

第10章 世界市場分析：薬剤コーティング別

  • イントロダクション/主な調査結果
  • 過去の市場規模・数量分析：薬剤コーティング別（2019年～2023年）
  • 現在・将来の市場規模・数量分析・予測：薬剤コーティング別（2024年～2033年）
    • パクリタキセル薬剤コーティング
    • シロリムス薬剤コーティング
    • その他
  • 薬剤コーティングの市場の魅力分析

第11章 世界市場分析：症状別

  • イントロダクション/主な調査結果
  • 過去の市場規模・数量分析：症状別（2019年～2023年）
  • 現在・将来の市場規模・数量分析・予測：症状別（2024年～2033年）
    • 末梢動脈疾患
    • 末梢動脈瘤
    • ステント内再狭窄
    • その他
  • 症状の市場の魅力分析

第12章 世界市場分析：動脈タイプ別

  • イントロダクション/主な調査結果
  • 過去の市場規模・数量分析：動脈タイプ別（2019年～2023年）
  • 現在・将来の市場規模・数量分析・予測：動脈タイプ別（2024年～2033年）
    • 頚動脈
    • フェムポップ動脈
    • 腸骨動脈
    • インフラポップ動脈
  • 動脈タイプ別の市場の魅力分析

第13章 世界市場分析：エンドユーザー別

  • イントロダクション/主な調査結果
  • 過去の市場規模・数量分析：エンドユーザー別（2019年～2023年）
  • 現在・将来の市場規模・数量分析・予測：エンドユーザー別（2024年～2033年）
    • 病院
    • 外来手術センター/外来患者
    • 心臓カテーテル検査室
  • エンドユーザー別の市場の魅力分析

第14章 世界市場分析：地域別

  • イントロダクション
  • 過去の市場規模・数量分析：地域別（2019年～2023年）
  • 現在・将来の市場金額・数量分析・予測：地域別（2024年～2033年）
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別市場の魅力分析

第15章 北米市場分析

第16章 ラテンアメリカ市場分析

第17章 欧州市場分析

第18章 東アジア市場分析

第19章 南アジア市場分析

第20章 オセアニア市場

第21章 中東・アフリカ市場分析

第22章 市場構造分析

  • 企業階層別の市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第23章 競合分析

  • 競合ダッシュボード
  • メーカーによるブランディングとプロモーション戦略
  • 主要開発分析
  • 競合の詳細
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Cook Medical Inc.
    • MicroPort Scientific Corporation（Endovastec（TM））
    • Medtronic Plc.
    • Cardinal Health, Inc.
    • B. Braun Melsungen AG
    • BIOTRONIK SE &Co. KG
    • Becton, Dickinson and Company
    • WL Gore &Associates Inc.
    • Getinge AB
    • Terumo Corp
    • Kyoto Medical Planning Co Ltd
    • iVascular SLU
    • AMG International GmbH
    • ENDOCOR GmbH
    • Meril Life Sciences Pvt. Ltd.
    • Nano Therapeutics Pvt Ltd
    • Koninklijke Philips NV
    • REVA Medical

第24章 使用される前提条件と頭字語

第25章 調査手法

目次
Product Code: PMRREP27211

Persistence Market Research has recently released a comprehensive report on the worldwide market for peripheral drug eluting balloons. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Peripheral Drug Eluting Balloons Market Size (2024E): USD 948.6Million
  • Projected Market Value (2033F): USD 1950.5 Million
  • Global Market Growth Rate (CAGR 2024 to 2033): 8.3%

Peripheral Drug Eluting Balloons Market - Report Scope:

Peripheral drug eluting balloons play a crucial role in the treatment of peripheral artery disease (PAD) by delivering medication directly to the arterial walls to inhibit restenosis and improve blood flow. These balloons are used in various healthcare settings, including hospitals, clinics, and outpatient centers, offering a range of drug formulations and balloon sizes to cater to different patient needs. Market growth is driven by the increasing prevalence of PAD, advancements in balloon technology, and a growing preference for minimally invasive procedures.

Market Growth Drivers:

The global peripheral drug eluting balloons market is propelled by several key factors, including the rising incidence of PAD, which affects millions of people worldwide. The demand for effective treatment options that offer sustained drug delivery and reduced restenosis rates is driving the adoption of drug eluting balloons. Technological advancements, such as the development of next-generation balloons with improved drug coatings and delivery mechanisms, enhance treatment efficacy and patient outcomes. Additionally, the increasing adoption of minimally invasive procedures and favorable reimbursement policies are further contributing to market growth.

Market Restraints:

Despite promising growth prospects, the peripheral drug eluting balloons market faces challenges related to regulatory compliance, high costs, and limited awareness in emerging markets. Stringent regulations governing the approval and use of drug eluting balloons impose significant compliance burdens on manufacturers. The high cost of these devices and associated procedures can also be a barrier to widespread adoption, particularly in regions with limited healthcare budgets. Furthermore, the lack of awareness about PAD and available treatment options in developing countries hinders market penetration.

Market Opportunities:

The peripheral drug eluting balloons market presents significant growth opportunities driven by technological innovations, demographic trends, and expanding healthcare infrastructure. The integration of advanced drug formulations and novel delivery technologies into balloon devices is expected to enhance therapeutic outcomes and broaden the application scope. Increasing investments in healthcare infrastructure, particularly in emerging economies, are anticipated to create new market opportunities. Strategic collaborations, investment in R&D, and the introduction of cost-effective solutions are essential to capitalize on these opportunities and sustain market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the peripheral drug eluting balloons market globally?
  • Which drug formulations and applications are driving the adoption of peripheral drug eluting balloons across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the peripheral drug eluting balloons market?
  • Who are the key players contributing to the peripheral drug eluting balloons market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global peripheral drug eluting balloons market?

Competitive Intelligence and Business Strategy:

Leading players in the global peripheral drug eluting balloons market, including Medtronic, B. Braun Melsungen AG, and Boston Scientific Corporation, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced drug eluting balloon solutions, including devices with enhanced drug coatings and delivery systems, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, medical device distributors, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving peripheral drug eluting balloons landscape.

Key Companies Profiled:

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Cook Medical Inc.
  • MicroPort Scientific Corporation (Endovastec(TM))
  • Medtronic Plc.
  • Cardinal Health, Inc.
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Becton, Dickinson and Company
  • W. L. Gore & Associates Inc.
  • Getinge AB
  • Terumo Corp
  • Kyoto Medical Planning Co Ltd
  • iVascular S.L.U
  • AMG International GmbH
  • ENDOCOR GmbH
  • Meril Life Sciences Pvt. Ltd.
  • Nano Therapeutics Pvt Ltd
  • Koninklijke Philips N.V.
  • REVA Medical

Key Segments of Peripheral Drug Eluting Balloons Industry Research

Drug Coating:

  • Paclitaxel Drug Coating
  • Sirolimus drug Coating

Indication:

  • Peripheral Arterial Disease
  • Peripheral Aneurysms
  • In-Stent Restenosis

Artery Type:

  • Carotid Arteries
  • Fem-Pop Arteries
  • Iliac Arteries
  • Infrapop Arteries

End User:

  • Hospitals
  • Ambulatory Surgical Centers/Outpatients
  • Cardiac Catheterization Labs

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Drug Coating Innovation / Development Trends

4. Value Added Insights

  • 4.1. Product Adoption/ Usage Analysis, by region
  • 4.2. Regulatory Scenario
  • 4.3. Technology Assessment
  • 4.4. Value Chain Analysis
  • 4.5. Recent Product Approvals and Launches
  • 4.6. Porter's Analysis
  • 4.7. Product USP Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Peripheral Vascular Devices Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Growth in Healthcare Spending
    • 5.2.2. Growth in Geriatric Population
    • 5.2.3. Rising Number of Peripheral Surgeries
    • 5.2.4. Technological Advancements
    • 5.2.5. Regulatory Landscape
    • 5.2.6. Cost of Procedures
    • 5.2.7. Product Adoption Rate and Demand
    • 5.2.8. Increase in Research and Development
    • 5.2.9. Pharmaceutical Industry Consolidation Activities
    • 5.2.10. Top Companies' Historical Growth
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug Coating
    • 6.1.2. By Indication
    • 6.1.3. By Artery Type
    • 6.1.4. By End User
    • 6.1.5. By Region
  • 6.2. 2024 Market Scenario

7. Global Market Demand in Volume (Units) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Volume (Units) Analysis, 2019-2023
  • 7.2. Current and Future Market Volume (Units) (Units) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis

8. Global Market - Pricing Analysis

  • 8.1. Regional Pricing Analysis By Drug Coating
  • 8.2. Pricing Break-up
    • 8.2.1. Manufacturer Level Pricing
    • 8.2.2. Distributor Level Pricing
  • 8.3. Global Average Pricing Analysis Benchmark
  • 8.4. Pricing Assumptions

9. Global Market Demand (in Value US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 9.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 9.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
    • 9.2.1. Y-o-Y Growth Trend Analysis
    • 9.2.2. Absolute $ Opportunity Analysis
  • 9.3. Revenue Opportunity Scenario

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Coating

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Drug Coating, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, by Drug Coating, 2024-2033
    • 10.3.1. Paclitaxel Drug Coating
    • 10.3.2. Sirolimus drug Coating
    • 10.3.3. Others
  • 10.4. Market Attractiveness Analysis, by Drug Coating

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Indication, 2024-2033
    • 11.3.1. Peripheral Arterial Disease
    • 11.3.2. Peripheral Aneurysms
    • 11.3.3. In-Stent Restenosis
    • 11.3.4. Others
  • 11.4. Market Attractiveness Analysis, by Indication

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Artery Type

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Mn) Analysis, By Artery Type, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Artery Type, 2024-2033
    • 12.3.1. Carotid Artery
    • 12.3.2. Fem-Pop Artery
    • 12.3.3. Iliac Artery
    • 12.3.4. Infrapop Artery
  • 12.4. Market Attractiveness Analysis, by Artery Type

13. Global Market Analysis 2019-2023 and Forecast 2024-2033, By End User

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by End User, 2024-2033
    • 13.3.1. Hospitals
    • 13.3.2. Ambulatory Surgical Centers/Outpatients
    • 13.3.3. Cardiac Catheterization Labs
  • 13.4. Market Attractiveness Analysis, by End User

14. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Region, 2019-2023
  • 14.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, By Region, 2024-2033
    • 14.3.1. North America
    • 14.3.2. Latin America
    • 14.3.3. Europe
    • 14.3.4. South Asia
    • 14.3.5. East Asia
    • 14.3.6. Oceania
    • 14.3.7. Middle East and Africa (MEA)
  • 14.4. Market Attractiveness Analysis, by Region

15. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. U.S.
      • 15.3.1.2. Canada
    • 15.3.2. By Drug Coating
    • 15.3.3. By Indication
    • 15.3.4. By Artery Type
    • 15.3.5. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug Coating
    • 15.4.3. By Indication
    • 15.4.4. By Artery Type
    • 15.4.5. By End User
  • 15.5. PESTLE Analysis
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis
  • 15.9. Country Level Analysis & Forecast
    • 15.9.1. U.S. Market Analysis
      • 15.9.1.1. Introduction
      • 15.9.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.9.1.2.1. By Drug Coating
        • 15.9.1.2.2. By Indication
        • 15.9.1.2.3. By Artery Type
        • 15.9.1.2.4. By End User
    • 15.9.2. Canada Market Analysis
      • 15.9.2.1. Introduction
      • 15.9.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.9.2.2.1. By Drug Coating
        • 15.9.2.2.2. By Indication
        • 15.9.2.2.3. By Artery Type
        • 15.9.2.2.4. By End User

16. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Mexico
      • 16.3.1.2. Brazil
      • 16.3.1.3. Argentina
      • 16.3.1.4. Rest of Latin America
    • 16.3.2. By Drug Coating
    • 16.3.3. By Indication
    • 16.3.4. By Artery Type
    • 16.3.5. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug Coating
    • 16.4.3. By Indication
    • 16.4.4. By Artery Type
    • 16.4.5. By End User
  • 16.5. PESTLE Analysis
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis
  • 16.9. Country Level Analysis & Forecast
    • 16.9.1. Mexico Market Analysis
      • 16.9.1.1. Introduction
      • 16.9.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.9.1.2.1. By Drug Coating
        • 16.9.1.2.2. By Indication
        • 16.9.1.2.3. By Artery Type
        • 16.9.1.2.4. By End User
    • 16.9.2. Brazil Market Analysis
      • 16.9.2.1. Introduction
      • 16.9.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.9.2.2.1. By Drug Coating
        • 16.9.2.2.2. By Indication
        • 16.9.2.2.3. By Artery Type
        • 16.9.2.2.4. By End User
    • 16.9.3. Argentina Market Analysis
      • 16.9.3.1. Introduction
      • 16.9.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.9.3.2.1. By Drug Coating
        • 16.9.3.2.2. By Indication
        • 16.9.3.2.3. By Artery Type
        • 16.9.3.2.4. By End User

17. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. Germany
      • 17.3.1.2. Italy
      • 17.3.1.3. France
      • 17.3.1.4. U.K.
      • 17.3.1.5. Spain
      • 17.3.1.6. BENELUX
      • 17.3.1.7. Russia
      • 17.3.1.8. Nordic Countries
      • 17.3.1.9. Rest of Europe
    • 17.3.2. By Drug Coating
    • 17.3.3. By Indication
    • 17.3.4. By Artery Type
    • 17.3.5. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug Coating
    • 17.4.3. By Indication
    • 17.4.4. By Artery Type
    • 17.4.5. By End User
  • 17.5. PESTLE Analysis
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis
  • 17.9. Country Level Analysis & Forecast
    • 17.9.1. Germany Market Analysis
      • 17.9.1.1. Introduction
      • 17.9.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.1.2.1. By Drug Coating
        • 17.9.1.2.2. By Indication
        • 17.9.1.2.3. By Artery Type
        • 17.9.1.2.4. By End User
    • 17.9.2. Italy Market Analysis
      • 17.9.2.1. Introduction
      • 17.9.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.2.2.1. By Drug Coating
        • 17.9.2.2.2. By Indication
        • 17.9.2.2.3. By Artery Type
        • 17.9.2.2.4. By End User
    • 17.9.3. France Market Analysis
      • 17.9.3.1. Introduction
      • 17.9.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.3.2.1. By Drug Coating
        • 17.9.3.2.2. By Indication
        • 17.9.3.2.3. By Artery Type
        • 17.9.3.2.4. By End User
    • 17.9.4. U.K. Market Analysis
      • 17.9.4.1. Introduction
      • 17.9.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.4.2.1. By Drug Coating
        • 17.9.4.2.2. By Indication
        • 17.9.4.2.3. By Artery Type
        • 17.9.4.2.4. By End User
    • 17.9.5. Spain Market Analysis
      • 17.9.5.1. Introduction
      • 17.9.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.5.2.1. By Drug Coating
        • 17.9.5.2.2. By Indication
        • 17.9.5.2.3. By Artery Type
        • 17.9.5.2.4. By End User
    • 17.9.6. BENELUX Market Analysis
      • 17.9.6.1. Introduction
      • 17.9.6.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.6.2.1. By Drug Coating
        • 17.9.6.2.2. By Indication
        • 17.9.6.2.3. By Artery Type
        • 17.9.6.2.4. By End User
    • 17.9.7. Russia Market Analysis
      • 17.9.7.1. Introduction
      • 17.9.7.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.7.2.1. By Drug Coating
        • 17.9.7.2.2. By Indication
        • 17.9.7.2.3. By Artery Type
        • 17.9.7.2.4. By End User
    • 17.9.8. Nordic Countries Market Analysis
      • 17.9.8.1. Introduction
      • 17.9.8.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.9.8.2.1. By Drug Coating
        • 17.9.8.2.2. By Indication
        • 17.9.8.2.3. By Artery Type
        • 17.9.8.2.4. By End User

18. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market End User (US$ Mn) Analysis, by Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. China
      • 18.3.1.2. Japan
      • 18.3.1.3. South Korea
    • 18.3.2. By Drug Coating
    • 18.3.3. By Indication
    • 18.3.4. By Artery Type
    • 18.3.5. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug Coating
    • 18.4.3. By Indication
    • 18.4.4. By Artery Type
    • 18.4.5. By End User
  • 18.5. PESTLE Analysis
  • 18.6. Market Trends
  • 18.7. Key Market Participants - Intensity Mapping
  • 18.8. Drivers and Restraints - Impact Analysis
  • 18.9. Country Level Analysis & Forecast
    • 18.9.1. China Market Analysis
      • 18.9.1.1. Introduction
      • 18.9.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.9.1.2.1. By Drug Coating
        • 18.9.1.2.2. By Indication
        • 18.9.1.2.3. By Artery Type
        • 18.9.1.2.4. By End User
    • 18.9.2. Japan Market Analysis
      • 18.9.2.1. Introduction
      • 18.9.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.9.2.2.1. By Drug Coating
        • 18.9.2.2.2. By Indication
        • 18.9.2.2.3. By Artery Type
        • 18.9.2.2.4. By End User
    • 18.9.3. South Korea Market Analysis
      • 18.9.3.1. Introduction
      • 18.9.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.9.3.2.1. By Drug Coating
        • 18.9.3.2.2. By Indication
        • 18.9.3.2.3. By Artery Type
        • 18.9.3.2.4. By End User

19. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. India
      • 19.3.1.2. Indonesia
      • 19.3.1.3. Malaysia
      • 19.3.1.4. Thailand
      • 19.3.1.5. Rest of South Asia
    • 19.3.2. By Drug Coating
    • 19.3.3. By Indication
    • 19.3.4. By Artery Type
    • 19.3.5. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Drug Coating
    • 19.4.3. By Indication
    • 19.4.4. By Artery Type
    • 19.4.5. By End User
  • 19.5. PESTLE Analysis
  • 19.6. Market Trends
  • 19.7. Key Market Participants - Intensity Mapping
  • 19.8. Drivers and Restraints - Impact Analysis
  • 19.9. Country Level Analysis & Forecast
    • 19.9.1. India Market Analysis
      • 19.9.1.1. Introduction
      • 19.9.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.9.1.2.1. By Drug Coating
        • 19.9.1.2.2. By Indication
        • 19.9.1.2.3. By Artery Type
        • 19.9.1.2.4. By End User
    • 19.9.2. Indonesia Market Analysis
      • 19.9.2.1. Introduction
      • 19.9.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.9.2.2.1. By Drug Coating
        • 19.9.2.2.2. By Indication
        • 19.9.2.2.3. By Artery Type
        • 19.9.2.2.4. By End User
    • 19.9.3. Malaysia Market Analysis
      • 19.9.3.1. Introduction
      • 19.9.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.9.3.2.1. By Drug Coating
        • 19.9.3.2.2. By Indication
        • 19.9.3.2.3. By Artery Type
        • 19.9.3.2.4. By End User
    • 19.9.4. Thailand Market Analysis
      • 19.9.4.1. Introduction
      • 19.9.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.9.4.2.1. By Drug Coating
        • 19.9.4.2.2. By Indication
        • 19.9.4.2.3. By Artery Type
        • 19.9.4.2.4. By End User

20. Oceania Market 2019-2023 and Forecast 2024-2033

  • 20.1. Introduction
  • 20.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
  • 20.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 20.3.1. By Country
      • 20.3.1.1. Australia
      • 20.3.1.2. New Zealand
    • 20.3.2. By Drug Coating
    • 20.3.3. By Indication
    • 20.3.4. By Artery Type
    • 20.3.5. By End User
  • 20.4. Market Attractiveness Analysis
    • 20.4.1. By Country
    • 20.4.2. By Drug Coating
    • 20.4.3. By Indication
    • 20.4.4. By Artery Type
    • 20.4.5. By End User
  • 20.5. PESTLE Analysis
  • 20.6. Market Trends
  • 20.7. Key Market Participants - Intensity Mapping
  • 20.8. Drivers and Restraints - Impact Analysis
  • 20.9. Country Level Analysis & Forecast
    • 20.9.1. Australia Market Analysis
      • 20.9.1.1. Introduction
      • 20.9.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 20.9.1.2.1. By Drug Coating
        • 20.9.1.2.2. By Indication
        • 20.9.1.2.3. By Artery Type
        • 20.9.1.2.4. By End User
    • 20.9.2. New Zealand Market Analysis
      • 20.9.2.1. Introduction
      • 20.9.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 20.9.2.2.1. By Drug Coating
        • 20.9.2.2.2. By Indication
        • 20.9.2.2.3. By Artery Type
        • 20.9.2.2.4. By End User

21. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

  • 21.1. Introduction
  • 21.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
  • 21.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 21.3.1. By Country
      • 21.3.1.1. GCC Countries
      • 21.3.1.2. Turkey
      • 21.3.1.3. Israel
      • 21.3.1.4. South Africa
      • 21.3.1.5. North Africa
      • 21.3.1.6. Rest of Middle East and Africa
    • 21.3.2. By Drug Coating
    • 21.3.3. By Indication
    • 21.3.4. By Artery Type
    • 21.3.5. By End User
  • 21.4. Market Attractiveness Analysis
    • 21.4.1. By Country
    • 21.4.2. By Drug Coating
    • 21.4.3. By Indication
    • 21.4.4. By Artery Type
    • 21.4.5. By End User
  • 21.5. PESTLE Analysis
  • 21.6. Market Trends
  • 21.7. Key Market Participants - Intensity Mapping
  • 21.8. Drivers and Restraints - Impact Analysis
  • 21.9. Country Level Analysis & Forecast
    • 21.9.1. GCC Countries Market Analysis
      • 21.9.1.1. Introduction
      • 21.9.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 21.9.1.2.1. By Drug Coating
        • 21.9.1.2.2. By Indication
        • 21.9.1.2.3. By Artery Type
        • 21.9.1.2.4. By End User
    • 21.9.2. Turkey Market Analysis
      • 21.9.2.1. Introduction
      • 21.9.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 21.9.2.2.1. By Drug Coating
        • 21.9.2.2.2. By Indication
        • 21.9.2.2.3. By Artery Type
        • 21.9.2.2.4. By End User
    • 21.9.3. Israel Africa Market Analysis
      • 21.9.3.1. Introduction
      • 21.9.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 21.9.3.2.1. By Drug Coating
        • 21.9.3.2.2. By Indication
        • 21.9.3.2.3. By Artery Type
        • 21.9.3.2.4. By End User
    • 21.9.4. South Africa Market Analysis
      • 21.9.4.1. Introduction
      • 21.9.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 21.9.4.2.1. By Drug Coating
        • 21.9.4.2.2. By Indication
        • 21.9.4.2.3. By Artery Type
        • 21.9.4.2.4. By End User
    • 21.9.5. North Africa Market Analysis
      • 21.9.5.1. Introduction
      • 21.9.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 21.9.5.2.1. By Drug Coating
        • 21.9.5.2.2. By Indication
        • 21.9.5.2.3. By Artery Type
        • 21.9.5.2.4. By End User

22. Market Structure Analysis

  • 22.1. Market Analysis, by Tier of Companies
  • 22.2. Market Share Analysis of Top Players
  • 22.3. Market Presence Analysis

23. Competition Analysis

  • 23.1. Competition Dashboard
  • 23.2. Branding and Promotional Strategies, By Manufacturers
  • 23.3. Key Development Analysis
  • 23.4. Competition Deep Dive
    • 23.4.1. Abbott Laboratories
      • 23.4.1.1. Overview
      • 23.4.1.2. Product Portfolio
      • 23.4.1.3. Sales Footprint
      • 23.4.1.4. Key Financials
      • 23.4.1.5. SWOT Analysis
      • 23.4.1.6. Key Developments
      • 23.4.1.7. Strategy Overview
        • 23.4.1.7.1. Marketing Strategy
        • 23.4.1.7.2. Product Strategy
        • 23.4.1.7.3. Channel Strategy
    • 23.4.2. Boston Scientific Corporation
      • 23.4.2.1. Overview
      • 23.4.2.2. Product Portfolio
      • 23.4.2.3. Sales Footprint
      • 23.4.2.4. Key Financials
      • 23.4.2.5. SWOT Analysis
      • 23.4.2.6. Key Developments
      • 23.4.2.7. Strategy Overview
        • 23.4.2.7.1. Marketing Strategy
        • 23.4.2.7.2. Product Strategy
        • 23.4.2.7.3. Channel Strategy
    • 23.4.3. Cook Medical Inc.
      • 23.4.3.1. Overview
      • 23.4.3.2. Product Portfolio
      • 23.4.3.3. Sales Footprint
      • 23.4.3.4. Key Financials
      • 23.4.3.5. SWOT Analysis
      • 23.4.3.6. Key Developments
      • 23.4.3.7. Strategy Overview
        • 23.4.3.7.1. Marketing Strategy
        • 23.4.3.7.2. Product Strategy
        • 23.4.3.7.3. Channel Strategy
    • 23.4.4. MicroPort Scientific Corporation (Endovastec(TM))
      • 23.4.4.1. Overview
      • 23.4.4.2. Product Portfolio
      • 23.4.4.3. Sales Footprint
      • 23.4.4.4. Key Financials
      • 23.4.4.5. SWOT Analysis
      • 23.4.4.6. Key Developments
      • 23.4.4.7. Strategy Overview
        • 23.4.4.7.1. Marketing Strategy
        • 23.4.4.7.2. Product Strategy
        • 23.4.4.7.3. Channel Strategy
    • 23.4.5. Medtronic Plc.
      • 23.4.5.1. Overview
      • 23.4.5.2. Product Portfolio
      • 23.4.5.3. Sales Footprint
      • 23.4.5.4. Key Financials
      • 23.4.5.5. SWOT Analysis
      • 23.4.5.6. Key Developments
      • 23.4.5.7. Strategy Overview
        • 23.4.5.7.1. Marketing Strategy
        • 23.4.5.7.2. Product Strategy
        • 23.4.5.7.3. Channel Strategy
    • 23.4.6. Cardinal Health, Inc.
      • 23.4.6.1. Overview
      • 23.4.6.2. Product Portfolio
      • 23.4.6.3. Sales Footprint
      • 23.4.6.4. Key Financials
      • 23.4.6.5. SWOT Analysis
      • 23.4.6.6. Key Developments
      • 23.4.6.7. Strategy Overview
        • 23.4.6.7.1. Marketing Strategy
        • 23.4.6.7.2. Product Strategy
        • 23.4.6.7.3. Channel Strategy
    • 23.4.7. B. Braun Melsungen AG
      • 23.4.7.1. Overview
      • 23.4.7.2. Product Portfolio
      • 23.4.7.3. Sales Footprint
      • 23.4.7.4. Key Financials
      • 23.4.7.5. SWOT Analysis
      • 23.4.7.6. Key Developments
      • 23.4.7.7. Strategy Overview
        • 23.4.7.7.1. Marketing Strategy
        • 23.4.7.7.2. Product Strategy
        • 23.4.7.7.3. Channel Strategy
    • 23.4.8. BIOTRONIK SE & Co. KG
      • 23.4.8.1. Overview
      • 23.4.8.2. Product Portfolio
      • 23.4.8.3. Sales Footprint
      • 23.4.8.4. Key Financials
      • 23.4.8.5. SWOT Analysis
      • 23.4.8.6. Key Developments
      • 23.4.8.7. Strategy Overview
        • 23.4.8.7.1. Marketing Strategy
        • 23.4.8.7.2. Product Strategy
        • 23.4.8.7.3. Channel Strategy
    • 23.4.9. Becton, Dickinson and Company
      • 23.4.9.1. Overview
      • 23.4.9.2. Product Portfolio
      • 23.4.9.3. Sales Footprint
      • 23.4.9.4. Key Financials
      • 23.4.9.5. SWOT Analysis
      • 23.4.9.6. Key Developments
      • 23.4.9.7. Strategy Overview
        • 23.4.9.7.1. Marketing Strategy
        • 23.4.9.7.2. Product Strategy
        • 23.4.9.7.3. Channel Strategy
    • 23.4.10. W. L. Gore & Associates Inc.
      • 23.4.10.1. Overview
      • 23.4.10.2. Product Portfolio
      • 23.4.10.3. Sales Footprint
      • 23.4.10.4. Key Financials
      • 23.4.10.5. SWOT Analysis
      • 23.4.10.6. Key Developments
      • 23.4.10.7. Strategy Overview
        • 23.4.10.7.1. Marketing Strategy
        • 23.4.10.7.2. Product Strategy
        • 23.4.10.7.3. Channel Strategy
    • 23.4.11. Getinge AB
      • 23.4.11.1. Overview
      • 23.4.11.2. Product Portfolio
      • 23.4.11.3. Sales Footprint
      • 23.4.11.4. Key Financials
      • 23.4.11.5. SWOT Analysis
      • 23.4.11.6. Key Developments
      • 23.4.11.7. Strategy Overview
        • 23.4.11.7.1. Marketing Strategy
        • 23.4.11.7.2. Product Strategy
        • 23.4.11.7.3. Channel Strategy
    • 23.4.12. Terumo Corp
      • 23.4.12.1. Overview
      • 23.4.12.2. Product Portfolio
      • 23.4.12.3. Sales Footprint
      • 23.4.12.4. Key Financials
      • 23.4.12.5. SWOT Analysis
      • 23.4.12.6. Key Developments
      • 23.4.12.7. Strategy Overview
        • 23.4.12.7.1. Marketing Strategy
        • 23.4.12.7.2. Product Strategy
        • 23.4.12.7.3. Channel Strategy
    • 23.4.13. Kyoto Medical Planning Co Ltd
      • 23.4.13.1. Overview
      • 23.4.13.2. Product Portfolio
      • 23.4.13.3. Sales Footprint
      • 23.4.13.4. Key Financials
      • 23.4.13.5. SWOT Analysis
      • 23.4.13.6. Key Developments
      • 23.4.13.7. Strategy Overview
        • 23.4.13.7.1. Marketing Strategy
        • 23.4.13.7.2. Product Strategy
        • 23.4.13.7.3. Channel Strategy
    • 23.4.14. iVascular S.L.U
      • 23.4.14.1. Overview
      • 23.4.14.2. Product Portfolio
      • 23.4.14.3. Sales Footprint
      • 23.4.14.4. Key Financials
      • 23.4.14.5. SWOT Analysis
      • 23.4.14.6. Key Developments
      • 23.4.14.7. Strategy Overview
        • 23.4.14.7.1. Marketing Strategy
        • 23.4.14.7.2. Product Strategy
        • 23.4.14.7.3. Channel Strategy
    • 23.4.15. AMG International GmbH
      • 23.4.15.1. Overview
      • 23.4.15.2. Product Portfolio
      • 23.4.15.3. Sales Footprint
      • 23.4.15.4. Key Financials
      • 23.4.15.5. SWOT Analysis
      • 23.4.15.6. Key Developments
      • 23.4.15.7. Strategy Overview
        • 23.4.15.7.1. Marketing Strategy
        • 23.4.15.7.2. Product Strategy
        • 23.4.15.7.3. Channel Strategy
    • 23.4.16. ENDOCOR GmbH
      • 23.4.16.1. Overview
      • 23.4.16.2. Product Portfolio
      • 23.4.16.3. Sales Footprint
      • 23.4.16.4. Key Financials
      • 23.4.16.5. SWOT Analysis
      • 23.4.16.6. Key Developments
      • 23.4.16.7. Strategy Overview
        • 23.4.16.7.1. Marketing Strategy
        • 23.4.16.7.2. Product Strategy
        • 23.4.16.7.3. Channel Strategy
    • 23.4.17. Meril Life Sciences Pvt. Ltd.
      • 23.4.17.1. Overview
      • 23.4.17.2. Product Portfolio
      • 23.4.17.3. Sales Footprint
      • 23.4.17.4. Key Financials
      • 23.4.17.5. SWOT Analysis
      • 23.4.17.6. Key Developments
      • 23.4.17.7. Strategy Overview
        • 23.4.17.7.1. Marketing Strategy
        • 23.4.17.7.2. Product Strategy
        • 23.4.17.7.3. Channel Strategy
    • 23.4.18. Nano Therapeutics Pvt Ltd
      • 23.4.18.1. Overview
      • 23.4.18.2. Product Portfolio
      • 23.4.18.3. Sales Footprint
      • 23.4.18.4. Key Financials
      • 23.4.18.5. SWOT Analysis
      • 23.4.18.6. Key Developments
      • 23.4.18.7. Strategy Overview
        • 23.4.18.7.1. Marketing Strategy
        • 23.4.18.7.2. Product Strategy
        • 23.4.18.7.3. Channel Strategy
    • 23.4.19. Koninklijke Philips N.V.
      • 23.4.19.1. Overview
      • 23.4.19.2. Product Portfolio
      • 23.4.19.3. Sales Footprint
      • 23.4.19.4. Key Financials
      • 23.4.19.5. SWOT Analysis
      • 23.4.19.6. Key Developments
      • 23.4.19.7. Strategy Overview
        • 23.4.19.7.1. Marketing Strategy
        • 23.4.19.7.2. Product Strategy
        • 23.4.19.7.3. Channel Strategy
    • 23.4.20. REVA Medical
      • 23.4.20.1. Overview
      • 23.4.20.2. Product Portfolio
      • 23.4.20.3. Sales Footprint
      • 23.4.20.4. Key Financials
      • 23.4.20.5. SWOT Analysis
      • 23.4.20.6. Key Developments
      • 23.4.20.7. Strategy Overview
        • 23.4.20.7.1. Marketing Strategy
        • 23.4.20.7.2. Product Strategy
        • 23.4.20.7.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology